Roswell Park Breast Surgery Chief Gives Keynote Talk on Immunotherapy for Breast Cancer

Address to Japan Society of Clinical Oncology focuses
on opportunities to expand benefits to more patients

  • Accomplished surgeon-scientist joined Roswell Park in 2016
  • Currently, immunotherapies work well for very few patients with breast cancer
  • Dr. Takabe also speaking on how to support development of oncology leaders
     
kazuaki_takabe_-_surgical_suite_october_18_2019_18_2.jpg

Dr. Kazuaki Takabe, Roswell Park’s Chief of Breast Surgery, gave the keynote address at the annual meeting of the Japan Society of Clinical Oncology.

BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center’s Chief of Breast Surgery, Kazuaki Takabe, MD, PhD, FACS, gave an Oct. 24 keynote address on immunotherapy for breast cancer at the 57th Annual Meeting of the Japan Society of Clinical Oncology (JSCO).

“Immunotherapy is becoming another major tool to fight many cancers, but breast cancer has been behind on this because it’s a cancer where we see very little lymphocyte infiltration, which is a major factor in whether these treatments will be effective,” notes Dr. Takabe, a surgeon-scientist who is also The Alfiero Foundation Endowed Chair in Breast Oncology and Professor of Oncology at the Buffalo, N.Y.-based cancer center. “Currently, immunotherapies for breast cancer are effective in only about 3% of patients. But we have a lot of opportunity to apply what we know toward making immunotherapy work for a much larger share of patients with the disease.”

Dr. Takabe joined Roswell Park’s faculty in 2016. His background includes training in general surgery both at the University of California, San Diego, and in Japan; specialized training in surgical oncology and service as an attending surgical oncologist and faculty member at the Medical College of Virginia Hospital, Virginia Commonwealth University School of Medicine; and postdoctoral training at the Salk Institute in La Jolla, California. 

On Friday, Oct. 25, Dr. Takabe also led a discussion on the roles of Japanese oncologists in global oncology and how JSCO’s U.S. counterpart, the American Society of Clinical Oncology, is addressing the challenge of developing future leaders.

The meeting, the theme of which is “Tackling the Needs of Society and Medicine,” continues through Oct. 26 at the Fukuoka International Congress Center in Fukuoka, Japan.

###


Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

Roswell Park Breast Surgery Chief Gives Keynote Talk on Immunotherapy for Breast Cancer

Roswell Park Breast Surgery Chief Gives Keynote Talk on Immunotherapy for Breast Cancer

Roswell Park

2 months
12 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Up Next Autoplay
EZH2 in Triple Negative Breast Cancer: What's Next in Research? @Ramon_Parsons @IcahnMountSinai
EZH2 in Triple Negative Breast Cancer: What's Next in Research? @Ramon_Parsons @IcahnMountSinai
Category: Breast Cancer
2 Views
Mount Sinai Health System 3 weeks
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
Category: Breast Cancer
44 Views
Mount Sinai Health System 3 weeks
SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine
SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine
Category: Breast Cancer
35 Views
ash 1 month
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Category: Breast Cancer
17 Views
Cancer-News 1 month
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19
Category: Breast Cancer
10 Views
ash 1 month
Prognostic Marker in Operable Breast Cancer #SABCS19
Prognostic Marker in Operable Breast Cancer #SABCS19
Category: Breast Cancer
24 Views
admin 1 month
The FLEX Real World Data #SABCS19 @BaptistHealthSA
The FLEX Real World Data #SABCS19 @BaptistHealthSA
Category: Breast Cancer
30 Views
admin 1 month
Agendia Presents New Data at #SABCS19 in Breast Cancer
Agendia Presents New Data at #SABCS19 in Breast Cancer
Category: Breast Cancer
10 Views
admin 1 month
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage...
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage...
Category: Breast Cancer
15 Views
Cancer-News 1 month
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
20 Views
cancernewsupdate 1 month